30€
60€
100€
150€

Home>News>YposKesi welcomes Alain Lamproye, an expert in industrial bioproduction, as its Chief Executive Officer

03 Mar 2017

YposKesi welcomes Alain Lamproye, an expert in industrial bioproduction, as its Chief Executive Officer

YposKesi, the first French pharmaceutical company to develop and manufacture gene and cell therapy products for rare diseases, created by the nonprofit organization AFM-Téléthon and the SPI fund managed by Bpifrance, have announced the appointment of Alain Lamproye as its Chief Executive Officer.

Alain Lamproye brings more than 25 years of experience in Europe and the United States in the field of industrial bioproduction. YposKesi will benefit from his unique expertise in bioproduction management and in the manufacturing of products generated from biotechnologies and gene therapy.

20 Mar 2018

The 31th Telethon edition reaches a final collection of 89,189,384 euros

On 8th and 9th December 2017, the Telethon enthralled the public throughout France.

14 Mar 2018

Spinal muscular atrophy : AveXis enters into licensing agreement with Genethon

AveXis, Inc. and Genethon today announced they have entered into an exclusive, worldwide license agreement for in vivo gene therapy delivery of AAV9 vector into the central nervous system (CNS) for the treatment of spinal muscular atrophy (SMA).

13 Feb 2018

Gene therapy: Généthon starts a clinical trial to test a gene therapy treatment for a rare liver disease, Crigler-Najjar Syndrome

Illustration for news: Gene therapy: Généthon starts a clinical trial to test a gene therapy treatment for a rare liver disease, Crigler-Najjar Syndrome

Généthon, a laboratory created by AFM-Téléthon, starts a European phase I/II clinical trial to test a treatment for Crigler-Najjar Syndrome, a rare liver disease.

All the news